# Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-incretin-mimetics-glp-1-receptor-agonists-evidence-3/ > **Published:** 2026-10-30T12:54:14-04:00 | **Last Modified / Clinically Audited:** 2026-10-30T12:54:14-04:00 > **Clinical Summary:** Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven […] --- Pharmacology & Safety Series Clinically Audited: October 2026 Table of Contents - [Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Incretin_Mimetics_038_GLP-1_Receptor_Agonists_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[Metabolic effects of a GLP-1 analog combined with aerobic training in ovariectomized rats](#Metabolic_effects_of_a_GLP-1_analog_combined_with_aerobic_training_in_ovariectomized_rats) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Incretin Mimetics & GLP-1 Receptor Agonists?](#Does_cannabis_or_CBD_interact_with_Incretin_Mimetics_038_GLP-1_Receptor_Agonists) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Incretin Mimetics & GLP-1 Receptor Agonists?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Incretin_Mimetics_038_GLP-1_Receptor_Agonists) - [Related](#Related) # Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids-most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)-are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). **Medications Impacted:** Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound). Featured Peer-Reviewed Investigation Molecular and cellular endocrinology (2027) ### Metabolic effects of a GLP-1 analog combined with aerobic training in ovariectomized rats **Lead Investigators:** Selau B, Bastos LM, Normann RS, Cubas GK, Herrmann ROCDC et al. | **Identifier:** PMID: 42727623 **Study Findings & Abstract:** Menopause is associated with visceral obesity, low-grade chronic inflammation, and increased risk of dyslipidemia, insulin resistance, and type 2 diabetes. Although exercise (EXE) and GLP-1 receptor agonists, such as semaglutide (SEM), have demonstrated beneficial effects on metabolic regulation, their combined impact in menopause models has been less investigated. In this study, ovariectomized female Wistar rats were divided into four experimental groups: sedentary plus saline (SED + SAL), sedentary plus semaglutide (SED + SEM), exercise (EXE + SAL), and EXE + SEM. The aerobic exercise protocol consisted of treadmill running at moderate intensity for four weeks, during which the rats received either SEM or SAL weekly. At the end of the protocol, metabolic parameters were assessed in blood, liver, soleus and gastrocnemius muscles. Both SEM groups had lower body weight, weight gain, relative subcutaneous white adipose tissue (scWAT) mass, glucose, total proteins, and triglycerides in serum and liver, while LDL cholesterol, glycogen in liver and gastrocnemius, and AMPK and HSF1 expression in gastrocnemius increased. EXE decreased total and LDL cholesterol, liver triglycerides and HSF1 expression in both tissues, while glycogen in liver and gastrocnemius, liver HSF1 expression and relative mass were increased. The combination of SEM + EXE increased glycogen content in the gastrocnemius and AMPK expression in both gastrocnemius and liver. This combined treatment reduced HDL levels, hepatic triglycerides and scWAT relative weight. These results suggest that SEM and EXE exert complementary effects on glycemic and lipid metabolism, with partially distinct metabolic outcomes that may involve different underlying mechanisms. [Access PubMed / DOI Reference Record →](https://doi.org/10.1016/j.mce.2026.112917) Dr. Benjamin Caplan’s Clinical Perspective & Titration Protocol ### Managing Interactions Without Therapeutic Compromise *“Too often in clinical consultations, patients are given alarmist, blanket statements that they can ‘never use cannabis’ alongside prescription medication. In truth, pharmacology is a science of doses, affinities, and kinetics. When co-managing patients on incretin mimetics & glp-1 receptor agonists, the goal is never to guess. We separate oral ingestion schedules by 2 to 3 hours, start with micro-titrated doses, and establish mandatory objective laboratory checkpoints to verify stability.”* **Mandatory Clinical Monitoring:** Symptom logs tracking gastrointestinal motility, post-ingestion latency, nausea scores, and blood glucose stability. **Clinical Authority Context:** Dr. Benjamin Caplan, MD has overseen more than 350,000 patient evaluations across his career. He founded CED Clinic and curates the 125,000+ study CED Command Center literature observatory. Frequently Asked Clinical Questions • Direct Answers #### Does cannabis or CBD interact with Incretin Mimetics & GLP-1 Receptor Agonists? Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). Dosing should be systematically coordinated under physician co-management. #### What monitoring or laboratory surveillance is required when taking cannabinoids alongside Incretin Mimetics & GLP-1 Receptor Agonists? Symptom logs tracking gastrointestinal motility, post-ingestion latency, nausea scores, and blood glucose stability. Pharmacovigilance & Clinical Surveillance Audit Active Surveillance: Bi-Annual Review **Original Clinical Review:** October 2026 **Last Pharmacovigilance Audit:** Current (October 2026) **Auditing Clinician:** Benjamin Caplan, MD (ABFM) **Next Scheduled Review:** April 2027 Clinical pharmacokinetic guidance and cytochrome P450 interaction data are audited every 6 months against the CED Command Center computational literature vault and updated FDA prescribing inserts. Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 1A/2A Caplan B. Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review. *CED Clinic Medication Safety & Pharmacology Series*. Published October 2026. https://cedclinic.com/cannabinoid-interactions-incretin-mimetics-glp-1-receptor-agonists-evidence/ [View Dr. Caplan’s Research & Bio →](https://cedclinic.com/drcaplan/) [Collaborative Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Complex Medication Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).